Scribe Therapeutics Reports Second Quarter 2026 Financial Results
Scribe Therapeutics, Inc. (SCTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to d
How this was made
The 30-second read
Why it matters
The combined financial and clinical milestones provide a strong catalyst for short‑term trading and longer‑term valuation.
Market read
First‑report of a sizable biotech IPO and Phase 1 trial start, offering actionable trading insight.
What to watch
Regulatory pathway uncertainties for epigenetic silencing therapies and competition from existing LDL‑C drugs.
Scribe Therapeutics reported second-quarter 2026 results, initiated the Phase 1 trial of STX-1150, received approximately $25.7 million in combined CIRM grants, and stated that IPO and private-placement proceeds extend funding into the first half of 2029.
The company advanced STX-1150 into a first-in-human Phase 1 trial and raised approximately $155.5 million in aggregate gross proceeds, but collaboration revenue declined to $1.9 million and the company remained loss-making with a $6.5 million net loss.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Collaboration revenueGAAP | $1.9M | – | – |
| Research and development expensesGAAP | $8.8M | – | – |
| General and administrative expensesGAAP | $2.5M | – | – |
| Total operating expensesGAAP | 11.31M | – | – |
| Loss from operationsGAAP | −9.39M | – | – |
| Interest income and other income (expense), netGAAP | 383K | – | – |
| Interest expenseGAAP | −276K | – | – |
| Change in fair value of Convertible NoteGAAP | 3.02M | – | – |
| Net loss before provision for income taxesGAAP | −6.26M | – | – |
| Provision for income taxGAAP | −212K | – | – |
| Net lossGAAP | $6.5M | – | – |
| Net loss per basic and diluted shareGAAP | $2.62 per basic and diluted share | – | – |
| Six-month collaboration revenueGAAP | 4.15M | – | – |
| Six-month research and development expensesGAAP | 20.13M | – | – |
| Six-month general and administrative expensesGAAP | 5.84M | – | – |
| Six-month total operating expensesGAAP | 25.97M | – | – |
| Six-month loss from operationsGAAP | −21.82M | – | – |
| Six-month interest income and other income (expense), netGAAP | 898K | – | – |
| Six-month interest expenseGAAP | −875K | – | – |
| Six-month change in fair value of Convertible NoteGAAP | −1.58M | – | – |
| Six-month net loss before provision for income taxesGAAP | −23.38M | – | – |
| Six-month provision for income taxGAAP | −441K | – | – |
| Six-month net lossGAAP | −23.82M | – | – |
| Cash, cash equivalents and investmentsGAAP | $43M | – | – |
| Total assetsGAAP | 57.93M | – | – |
| Total liabilitiesGAAP | 102.4M | – | – |
| Total stockholders' deficitGAAP | −164.8M | – | – |
first half of 2027 and first half of 2029 outlook
- NoteInitial clinical data, including safety, tolerability, and LDL-C lowering activity, from the single ascending dose portion of the STX-1150 Phase 1 trial is anticipated in the first half of 2027.
- NoteSTX-1200 is being advanced toward clinical entry as early as 2027.
- NoteSTX-1400 is being advanced toward clinical entry as early as 2027.
- NoteExisting cash, cash equivalents, and investments, together with net proceeds from the IPO and concurrent private placement, are expected to fund operating expenses and capital expenditure requirements into the first half of 2029.
What drove it
- Collaboration revenue decreased primarily because of lower reimbursable research and development activities and reduced revenue recognition under collaboration arrangements.
- Research and development expenses decreased primarily because of lower personnel-related costs and reduced spending on preclinical research programs, partially offset by increased clinical and manufacturing expenditures supporting the STX-1150 Phase 1 trial.
- General and administrative expenses decreased primarily because of lower administrative costs.
- Scribe initiated the first-in-human Phase 1 trial of STX-1150 in Australia in mid-2026.
- CIRM awarded $12.7 million for advancing STX-1200 and $13.0 million for advancing STX-1400.
Concerns
- Collaboration revenue was $1.9 million for the three months ended June 30, 2026, compared with $4.9 million for the prior-year period.
- The company reported a net loss of $6.5 million for the three months ended June 30, 2026.
- Cash, cash equivalents, and marketable securities were $43.0 million as of June 30, 2026, before the July 2026 IPO and concurrent private placement.
- Total liabilities were 102,417 (in thousands) and total stockholders' deficit was (164,846) (in thousands) as of June 30, 2026.
- Clinical data from STX-1150 are not anticipated until the first half of 2027.
What to watch
- Initial safety, tolerability, and LDL-C lowering activity from the single ascending dose portion of the STX-1150 Phase 1 trial in the first half of 2027.
- Progress of STX-1200 and STX-1400 toward clinical entry as early as 2027.
- Deployment of approximately $25.7 million in combined non-dilutive CIRM grants for STX-1200 and STX-1400.
- The company's execution against its stated funding runway into the first half of 2029.
Balance sheet and cash flow
- Cash, cash equivalents, and marketable securities were $43.0 million as of June 30, 2026, compared with $58.0 million as of December 31, 2025.
- The IPO, full exercise of the underwriters’ option, and concurrent private placement totaled approximately $155.5 million in aggregate gross proceeds before underwriting discounts, commissions, and offering expenses.
- The July 2026 IPO and concurrent private placement raised approximately $140.6 million of net proceeds.
- Total assets were 57,927 (in thousands) as of June 30, 2026, compared with 78,219 (in thousands) as of December 31, 2025.
- Total liabilities were 102,417 (in thousands) as of June 30, 2026, compared with 101,282 (in thousands) as of December 31, 2025.
- Total stockholders' deficit was (164,846) (in thousands) as of June 30, 2026, compared with (143,419) (in thousands) as of December 31, 2025.
Analysis
Scribe reported collaboration revenue of $1.9 million for the second quarter of 2026, compared with $4.9 million in the prior-year period. The company attributed the decline to lower reimbursable research and development activity and reduced revenue recognition under its collaboration arrangements. Research and development expenses were $8.8 million, compared with $13.9 million, while general and administrative expenses were $2.5 million, compared with $2.6 million. Net loss was $6.5 million, or $2.62 per basic and diluted share, compared with a net loss of $9.9 million, or $4.08 per basic and diluted share.
The operating profile reflected reduced personnel-related costs and lower preclinical research spending, partially offset by clinical and manufacturing spending for STX-1150. The six-month statement showed collaboration revenue of 4,151 (in thousands), research and development expense of 20,128 (in thousands), and a six-month net loss of (23,824) (in thousands). The filing also reported a six-month loss from operations of (21,821) (in thousands), compared with (17,185) (in thousands) in the prior-year period.
The principal operational development was initiation of the first-in-human Phase 1 trial of STX-1150 in Australia. STX-1150 is designed to repress PCSK9 transcription for LDL-C lowering without permanently altering the underlying DNA sequence. Scribe expects initial data covering safety, tolerability, and LDL-C lowering activity from the single ascending dose portion in the first half of 2027. Separately, the company received CIRM awards of $12.7 million for STX-1200 and $13.0 million for STX-1400, both of which are being advanced toward clinical entry as early as 2027.
Liquidity changed materially after period end. Cash, cash equivalents, and marketable securities were $43.0 million as of June 30, 2026, compared with $58.0 million as of December 31, 2025. In July 2026, the IPO, underwriters’ option exercise, and concurrent Sanofi private placement generated approximately $155.5 million in aggregate gross proceeds and approximately $140.6 million in net proceeds. Management stated that existing cash, cash equivalents, and investments together with these net proceeds are sufficient to fund operating expenses and capital expenditure requirements into the first half of 2029.
The key near-term focus is clinical execution rather than commercial revenue growth. Collaboration revenue declined, while the company continues to report losses and a total stockholders' deficit of (164,846) (in thousands) as of June 30, 2026. The first-half 2027 STX-1150 clinical readout, progress of STX-1200 and STX-1400 toward clinical entry, and use of the IPO, private-placement, and CIRM funding are the reported milestones that frame the next stage of development.
Management, verbatim
The second quarter and the weeks immediately following represented a transformational period for Scribe.
Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe Therapeutics
We advanced our lead silencing asset STX-1150 into the clinic, secured significant grant support from CIRM to develop our next two cardiometabolic assets, and successfully completed our initial public offering.
Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe Therapeutics
Not in the filing
stated, not guessed- Gross margin and gross profit were not reported.
- Non-GAAP measures were not reported.
- Operating cash flow was not reported.
- Free cash flow was not reported.
- Debt balance was not reported as a balance-sheet line item.
- Share repurchases and dividends were not reported.
- Reportable segment revenue was not reported.
- Quarter-over-quarter comparisons were not reported.
- Percentage year-over-year changes were not reported for the financial metrics.
- Tax rate was not reported.
- Revenue, gross-margin, operating-expense, and tax-rate financial guidance were not reported.
- Weighted-average shares outstanding were not reported.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Scribe Therapeutics, a Nasdaq‑listed CRISPR biotech, disclosed its Q2 financials, a successful IPO, and initiation of its lead LDL‑C program.
Ticker impact
Scribe Therapeutics filed an 8‑K reporting Q2 2026 results, a $155.5 M IPO and private placement, and the start of a Phase 1 trial for STX‑1150.
Potential upside as cash runway extends and clinical data is expected in H1 2027.
Large fresh financing and first‑in‑human trial are material catalysts for a clinical‑stage biotech.
Market effects
Highlights growing investor interest in CRISPR‑based epigenetic therapies within biotech.
Adds to recent capital raising activity among US‑listed biotech firms.
May influence global biotech funding trends and partnerships, e.g., Sanofi involvement.
Counterpoint
The early‑stage nature of the trial and lack of revenue could limit upside; dilution from IPO may pressure price.
Key entities
- CompanyScribe Therapeutics, Inc.
Clinical‑stage biotech developing epigenetic CRISPR therapies.
- InvestorSanofi
Participated in the concurrent private placement at IPO price.
